Advances in™ Cardiology: Emerging Treatments for Hypercholesteremia in Statin Intolerant Patient Populations: What Options Do You Have?

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of statin-resistant hypercholesterolemia, with a forward-looking perspective on how novel agents might impact clinical practice. The emerging therapies for treating patients with hypercholesterolemia will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Statins are the cornerstone pharmacologic therapy to manage hypercholesterolemia, but a relatively large segment of patients with hypercholesterolemia remain at residual risk of cardiovascular disease despite use of these agents. This may be due, in part, to statin intolerance and to the severity of cholesterol elevation, as seen in patients with familial hypercholesterolemia (FH). Newer, nonstatin therapies are now available. These include PCSK9 inhibitors, cholesterol absorption inhibitors (eg, ezetimibe), bempedoic acid, and inclisiran.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Esperion Therapeutics Inc.

Target Audience

This online educational activity is directed toward cardiologists, specialty NPs and PAs, and primary care physicians engaged in the care of patients with hypercholesteremia.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify appropriate patients who require non-statin therapies for hypercholesterolemia, based on recent guidelines
• Describe the efficacy and safety of approved and emerging non-statin drugs for hypercholesterolemia
• Characterize the mechanism of action of approved and emerging non-statin drugs for hypercholesterolemia
• Explain common barriers to patient adherence to cholesterol-lowering therapy and approaches to identifying and addressing barriers

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
Clinical Assistant Professor of Medicine
New York University Medical School
New York University Center for the Prevention of Cardiovascular Disease
Director
Bellevue Hospital Lipid Clinic
New York, NY

Disclosures: Grant/Research Support: Aegerion Pharmaceuticals, Pfizer. Consultant: Amarin, Amgen, Ambry Genetics. Speaker's Bureau: Amgen, Amarin, Akcea Therapeutics, Alexion Pharmaceuticals, Sanofi, Regeneron. Other Support: Advisory Boards: Amgen, Sanofi, Regeneron, Akcea Therapeutics, Aegerion Pharmaceuticals, Alexion Pharmaceuticals, Ambry Genetics.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.